antiresorptive

antiresorptive

(ant?i-re-sorp'tiv, -zorp') [ anti- + L. resorbere, to suck in]
1. Blocking or opposing the destruction of bone by osteoclasts.
2. An agent that prevents or slows the progress of osteoporosis. See: osteoporosis
References in periodicals archive ?
The findings also reinforce the general strategy of treating with anabolic therapy followed by an antiresorptive agent, rather than the other way around.
announced today that Chugai filed a new drug application to the Ministry of Health, Labour and Welfare for the oral formulation of bisphosphonate antiresorptive agent which was co-developed by the two companies for the indication of osteoporosis.
Consider avoiding the use of an antiresorptive agent during the drug holiday," Dr.
A position paper on Medication Related Osteonecrosis of the Jaw (MRONJ), released by the American Association of Oral and Maxillofacial Surgeons, expands the scope of the condition previously referred to as Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) and changes its name to reflect the antiresorptive (denosumab) and antiangiogenic therapies that have recently been associated with the condition.
It is also the most widely prescribed antiresorptive for treatment of osteoporosis globally and has been clinically studied for over 18 years.
20) There have been a number of recent studies suggesting additive effects on bone mineral density when teriparatide is used with antiresorptive drugs.
Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude.
MINNEAPOLIS--Combining the antiresorptive denosumab with the anabolic agent teriparatide increased bone mineral density more than either drug alone in postmenopausal women at high fracture risk in the ongoing DATA study.
In addition to blood transfusions and iron chelation therapy; hormonal replacement therapy, calcium and vitamin D supplementation; antiresorptive drugs like bisphosphonates are used to inhibit osteoclast function.
com)-- On the heels of an earlier study linking antiresorptive drugs to medication induced osteonecrosis of the jaw, or ONJ, researchers at the Columbia University of Dental Medicine have found that a specific genetic variation can raise the risk of this disease developing.